Compare KPTI & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KPTI | ELUT |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 172.6M | 46.5M |
| IPO Year | 2013 | 2020 |
| Metric | KPTI | ELUT |
|---|---|---|
| Price | $8.15 | $1.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | ★ $17.50 | $6.00 |
| AVG Volume (30 Days) | ★ 603.7K | 180.6K |
| Earning Date | 02-12-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 146.77 |
| EPS | N/A | ★ 0.87 |
| Revenue | ★ $146,067,000.00 | $12,293,000.00 |
| Revenue This Year | N/A | $26.95 |
| Revenue Next Year | $46.62 | $24.84 |
| P/E Ratio | ★ N/A | $1.26 |
| Revenue Growth | ★ 0.57 | N/A |
| 52 Week Low | $3.51 | $0.50 |
| 52 Week High | $10.99 | $3.15 |
| Indicator | KPTI | ELUT |
|---|---|---|
| Relative Strength Index (RSI) | 45.98 | 49.02 |
| Support Level | $5.60 | $0.89 |
| Resistance Level | $8.95 | $1.15 |
| Average True Range (ATR) | 0.73 | 0.13 |
| MACD | -0.16 | -0.02 |
| Stochastic Oscillator | 31.09 | 19.10 |
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.